Eurogentec to acquire AnaSpec
Eurogentec, a Belgian supplier of reagents, kits, specialist products and custom services to the life science, biotechnology, pharmaceutical and diagnostic markets, is to strengthen its US presence with the acquisition of AnaSpec, a privately owned proteomics company based in Fremont, California.
Eurogentec, a Belgian supplier of reagents, kits, specialist products and custom services to the life science, biotechnology, pharmaceutical and diagnostic markets, is to strengthen its US presence with the acquisition of AnaSpec, a privately owned proteomics company based in Fremont, California.
AnaSpec provides integrated proteomics solutions for life science research and diagnostics. The company has expertise in peptides synthesis, labelled peptides and antibodies, fluorescent dyes and enzyme activity assays.
"Through this acquisition Eurogentec becomes a leading integrated solution provider for the life science and diagnostics sectors," said Jean-Pierre Delwart, ceo of Eurogentec.
"Our combined expertise enables Eurogentec to provide innovative solutions in the fields of genomics and proteomics for basic research in the biotech and pharmaceutical sectors, as well as applied solutions in the diagnostics sector."
AnaSpec's HiLyte Fluor dyes and QXL quenchers will be integrated into Eurogentec's portfolio of oligonucleotides to establish an alternative to dye-labelled oligonucleotides for commercial and diagnostic applications.
"It is important for the sustained development of AnaSpec to integrate into a larger organisation where its current assets and competencies can bring real added value," said AnaSpec's founders, Anita and Frank Hong. They will remain at AnaSpec to grow its businesses. Eurogentec intends to maintain AnaSpec's Fremont facility and its employees.
Eurogentec is headquartered in LiEge, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland. It has additional production facilities in North America, Japan and Singapore and employs more than 400 people globally.
